Bionano Genomics Inc Stock Price, News & Analysis

Bionano Genomics (BNGO) announced preliminary Q4 revenue estimates between $5.8 million and $6.2 million, marking a significant increase of 45%-55% over Q4 2020. The company has achieved full-year revenue expectations of approximately $17.5 million to $17.9 million, a growth of 106%-110% compared to 2020. Additionally, it reported a 69% increase in installed systems, totaling 164 by year-end 2021. Bionano exceeded its goals for the year and anticipates strong momentum into 2022, bolstered by advancements in its technologies and clinical trials.

Bionano Genomics (BNGO) recently showcased advancements in optical genome mapping (OGM) at its 2022 Symposium, highlighting its applications in hematologic malignancies. Ten presentations from leading researchers demonstrated OGM's ability to detect structural variants, revealing novel genetic aberrations in conditions like B-cell Chronic Lymphocytic Leukemia (B-CLL) and Acute Lymphoblastic Leukemia (ALL). OGM was noted for being faster and more cost-effective than traditional methods, increasing both accuracy and efficiency in genetic analysis.

Bionano Genomics (BNGO) launched its 2022 Symposium, showcasing the effectiveness of optical genome mapping (OGM) in clinical research for genetic diseases. The event featured six presentations from leading researchers, demonstrating OGM's superior sensitivity, resolution, and efficiency compared to traditional genetic testing methods. Studies revealed high concordance rates of OGM with known chromosomal abnormalities and successful identification of complex structural variants. Moreover, OGM's potential in reproductive medicine was highlighted, showing promise for improving IVF outcomes. 37 posters were presented, with top awards being given in various categories.

Bionano Genomics hosted the first day of its 2022 Symposium, showcasing advancements in optical genome mapping (OGM) for diverse clinical applications. Six presentations highlighted OGM's advantages over traditional methods, demonstrating improved sensitivity and faster results in evaluating genetic diseases. Notable discussions included OGM's role in identifying structural variants and applications in reproductive medicine. The event also honored poster presentations across four categories, emphasizing ongoing research in OGM. The symposium aims to enhance understanding and integration of OGM into clinical practices.

Bionano Genomics (BNGO) reported promising interim results from its ongoing clinical trial to evaluate optical genome mapping (OGM) as a potential new standard of care (SOC) for genetic disease diagnosis. The study involved 331 sample runs across 202 subjects, achieving 97.7% concordance with SOC. Key findings include a first-pass success rate of 94% and 100% concordance for pathogenic variant calls. The trial enrolled 813 subjects overall, with the expectation of impactful outcomes that could revolutionize genetic testing practices.

Bionano Genomics (BNGO) announced its upcoming virtual Symposium from January 10-13, 2022, featuring 31 oral presentations from 27 customers worldwide. This annual event will highlight the applications of optical genome mapping (OGM) in genetic disease and cancer research.

With 45% of presentations from North America and 55% from Europe, participants will explore OGM's role across various domains, including constitutional cytogenomics and hematologic malignancies.

Registration is free and aims to connect OGM users and demonstrate advancements in genomic analysis.

Bionano Genomics (BNGO) announced the completion of its first prototype for a new single molecule imaging system aimed at improving optical genome mapping (OGM). This prototype will be tested to meet the demands of high-volume users, with the commercial system projected for release in the first half of 2023. The new system is expected to significantly enhance throughput, imaging up to 820 Gbp per hour compared to the current Saphyr system’s 205 Gbp. It will also offer flexible workflows, allowing simultaneous processing of diverse samples.

Bionano Genomics (BNGO) has announced that University Hospitals Leuven in Belgium has expanded its BELAC-accredited menu to include assays for acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and facioscapulohumeral muscular dystrophy (FSHD). This expansion follows their previous accreditation for acute lymphoblastic leukemia (ALL) analyses. The new optical genome mapping (OGM) workflows significantly reduced costs and turnaround times while increasing the success rates in identifying pathogenic variants. Bionano's CEO believes this achievement sets a precedent for other labs to adopt OGM.

Bionano Genomics, Inc. (BNGO) announced the appointment of Vincent Wong to its board of directors. Mr. Wong has extensive experience in commercial leadership, including nearly 18 years at Roche Diagnostics, where he held senior roles in product marketing, sales, and business development. His expertise is expected to enhance Bionano's commercial execution and market access strategies for its optical genome mapping solutions. CEO Erik Holmlin expressed optimism about Wong's contribution to the company’s growth and innovation in genomics.